Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer&#39;s disease.

Elayta (zervimesine) - Cognition Therap

http://www.ncbi.nlm.nih.gov/pubmed/41943055

Anthony O Caggiano; Britney N Lizama; Charlotte E Teunissen; Duc Duong; Eunah Cho; Henrik Zetterberg; Jill Thiel; Kaj Blennow; Kiran Pandey; Marleen J A Koel-Simmelink; Mary E Hamby; Michael Grundman; Nicholas T Seyfried; Valentina Di Caro

Apr 8, 2026